Merck Canada Inc. has announced the availability of the new Gardasil 9 HPV vaccine, following approval by Health Canada.
The Gardasil 9 vaccine helps prevent against diseases associated with the HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. These nine HPV types are known to cause approximately 90% of cervical cancers, 80% of cervical precancers, 75% of HPV-related vulvar, vaginal and anal cancers and precancers, and over 90% of genital warts.
The vaccine is indicated for girls and women aged 9 to 45 and for boys and men aged 9 to 26. The SOGC recommends HPV vaccination using Gardasil 9 for all Canadians of these respective age groups.
The SOGC congratulates Merck Canada Inc. for advancing the development of a new HPV vaccine and for providing increased protection against reproductive cancers among Canadians.
